Abstract
Background: In patients with relapsing-remitting multiple sclerosis (RRMS), disease-modifying therapies (DMTS) dimethyl fumarate (DMF) and interferon beta-1a (IFNβ-1a) reduce total lymphocyte counts (TLCS), which are potentially associated with increased infection risk in real-world settings. Data on these outcomes in older patients are lacking. This study compared infection rates and lymphocyte counts in RRMS patients ≥50 years old receiving subcutaneous (SC) IFNβ-1a 44 mcg 3 times-per-week or DMF 240mg twice-daily.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
